Stock CGON CG ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News CG Oncology, Inc.

Equities

CGON

US1569441009

Real-time Estimate Cboe BZX
Other stock markets
 01:46:54 2024-06-12 pm EDT 		5-day change 1st Jan Change
35.22 USD +0.06% Intraday chart for CG Oncology, Inc. -2.78% 0.00%
Jun. 06 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CI
May. 24 Sector Update: Health Care Stocks Softer in Friday Afternoon Trading MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
AQ
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CI
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading
MT
CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint
MT
CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint
MT
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
AQ
CG Oncology, Inc. to Present Positive Final Results from Phase 2 Core-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC At Asco 2024 Annual Meeting
CI
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target
MT
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
AQ
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin
CI
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
AQ
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
AQ
PACS Group to raise $450 mln in US IPO at over $3 bln valuation
RE
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
AQ
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P TMI Index
CI
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGON Stock
  4. News CG Oncology, Inc.